Circulating Tumor Cell PD-L1 and Peripheral Blood CD8 T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.
1/5 보강
[BACKGROUND] Circulating tumor cells (CTCs) and peripheral T-cell immune checkpoints offer minimally invasive biomarkers for immune checkpoint inhibitor (ICI) therapy.
- p-value p<0.001
- p-value p=0.021
- 95% CI 0.32-0.72
- HR 0.48
APA
Guan S, Huangfu J, et al. (2026). Circulating Tumor Cell PD-L1 and Peripheral Blood CD8 T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.. Cancer management and research, 18, 580857. https://doi.org/10.2147/CMAR.S580857
MLA
Guan S, et al.. "Circulating Tumor Cell PD-L1 and Peripheral Blood CD8 T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.." Cancer management and research, vol. 18, 2026, pp. 580857.
PMID
41873417
Abstract
[BACKGROUND] Circulating tumor cells (CTCs) and peripheral T-cell immune checkpoints offer minimally invasive biomarkers for immune checkpoint inhibitor (ICI) therapy. We assessed whether a dual biomarker combining PD-L1 on CTCs and PD-1 on circulating CD8 T cells is associated with outcomes in advanced non-small cell lung cancer (NSCLC).
[METHODS] We retrospectively enrolled stage IIIB-IV NSCLC patients treated with anti-PD-1/PD-L1 agents (any line) from January 2022 to December 2023. Eligibility required pretreatment blood and evaluable dual-biomarker testing; all 126 included patients had successful CTC assessment and flow-cytometric CD8 T-cell PD-1 measurement. Patients were classified as CTC PD-L1-positive if ≥1 CTC showed membranous and/or cytoplasmic PD-L1 staining. CD8 PD-1high was defined by the cohort median PD-1+ fraction (35.6%). Patients were stratified by CTC PD-L1 status and CD8 PD-1 (high/low). The primary endpoint was progression-free survival (PFS); overall survival (OS) and objective response rate (ORR) were secondary endpoints.
[RESULTS] Fifty-seven patients (45.2%) were CTC PD-L1-positive. Median PFS was longest in the PD-L1/PD-1high group (14.2 months) versus the other three groups (8.5, 6.3, and 4.8 months; p<0.001). ORR followed a similar gradient (41.9%, 30.8%, 22.9%, and 14.7%; p=0.021). After adjustment for baseline covariates, dual-biomarker status remained independently associated with PFS (HR=0.48, 95% CI 0.32-0.72; p<0.001) and OS (HR=0.53, 95% CI 0.35-0.80; p=0.002).
[CONCLUSION] This dual liquid-biopsy approach was associated with response and survival in this retrospective advanced NSCLC cohort receiving ICIs, supporting its potential for prognostic stratification; prospective validation is needed.
[METHODS] We retrospectively enrolled stage IIIB-IV NSCLC patients treated with anti-PD-1/PD-L1 agents (any line) from January 2022 to December 2023. Eligibility required pretreatment blood and evaluable dual-biomarker testing; all 126 included patients had successful CTC assessment and flow-cytometric CD8 T-cell PD-1 measurement. Patients were classified as CTC PD-L1-positive if ≥1 CTC showed membranous and/or cytoplasmic PD-L1 staining. CD8 PD-1high was defined by the cohort median PD-1+ fraction (35.6%). Patients were stratified by CTC PD-L1 status and CD8 PD-1 (high/low). The primary endpoint was progression-free survival (PFS); overall survival (OS) and objective response rate (ORR) were secondary endpoints.
[RESULTS] Fifty-seven patients (45.2%) were CTC PD-L1-positive. Median PFS was longest in the PD-L1/PD-1high group (14.2 months) versus the other three groups (8.5, 6.3, and 4.8 months; p<0.001). ORR followed a similar gradient (41.9%, 30.8%, 22.9%, and 14.7%; p=0.021). After adjustment for baseline covariates, dual-biomarker status remained independently associated with PFS (HR=0.48, 95% CI 0.32-0.72; p<0.001) and OS (HR=0.53, 95% CI 0.35-0.80; p=0.002).
[CONCLUSION] This dual liquid-biopsy approach was associated with response and survival in this retrospective advanced NSCLC cohort receiving ICIs, supporting its potential for prognostic stratification; prospective validation is needed.
같은 제1저자의 인용 많은 논문 (5)
- A multi-dimensional omics framework identifies GPR35 as a driver of M2 macrophage activation and poor prognosis in colorectal cancer.
- Enhanced antitumor efficacy of combined targeting of adenosine A receptor and PD-1 is mediated via multiple effects on different cell populations within tumor microenvironment.
- Fear of cancer recurrence mediates the association between symptom burden and readiness for return to work in patients with lung cancer.
- Optical phenotyping using label-free microscopy and deep learning.
- Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy.